EVENTS · INCY
PEERS
EARNINGS
No company news, with the biotechnology group also higher as a day of broad gains across the Health Care sector
Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and immune-mediated conditions. Incyte Corp. develops both small-molecule medicines and biologics, and its marketed therapies support patients with a range of specialty disease areas, including dermatology and rare hematologic disorders. The company also maintains a pipeline of clinical-stage candidates across its core therapeutic franchises, reflecting its role as a research-driven developer of targeted treatments. Headquartered in Wilmington, Delaware, Incyte Corp. serves healthcare markets in the United States and internationally through its commercial and development activities.
| Series | 1W | 1M |
|---|---|---|
| INCY | +5.1% | +9.0% |
| Peers | +1.7% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 53 | 52 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | −4.27 | −3.60 | +15.69% | +3.01% |
| Q2 FY2026 | 2.14 | 3.09 | +44.14% | +6.92% |
| Q1 FY2026 | 1.40 | 1.81 | +29.43% | +3.53% |
| Q4 FY2025 | 1.97 | 1.80 | −8.46% | −9.35% |
| Q3 FY2025 | — | — | — | −3.12% |
| Series | 1W | 1M |
|---|---|---|
| INCY | +5.1% | +9.0% |
| Peers | +1.7% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 53 | 52 |
